Endogenex

Endogenex is a clinical-stage company based in Minneapolis, Minnesota, dedicated to developing innovative treatments for individuals with type 2 diabetes (T2D). Founded in collaboration with Mayo Clinic, the company focuses on resetting the body's metabolic signaling system to enhance metabolic function and improve patient outcomes. The core innovation of Endogenex is the ReCET™ System, which utilizes controlled, non-thermal pulsed electric fields delivered through an endoscopic procedure. This technology aims to help patients manage their blood glucose levels and slow the progression of T2D by addressing the underlying disease processes. The company is actively engaged in clinical development and trials to validate the safety and efficacy of this novel approach. Endogenex primarily serves individuals living with type 2 diabetes who are looking for new therapeutic options beyond traditional medications. The leadership team, including CEO Stacey Pugh, brings expertise in medical devices and healthcare innovation, positioning the company to make significant advancements in diabetes treatment.

• Employees 25
• Founded 2017
• Annual Revenue $7800000
• Total Funding $140290355